- Full Year 2024 Syncona Ltd Earnings Call Transcript3 days ago£1.12 (-1.06%)Earnings
- Half Year 2024 Syncona Ltd Earnings Call TranscriptNov 16, 2023£1.29 (-4.15%)Earnings
- Full Year 2023 Syncona Ltd Earnings Call TranscriptJun 15, 2023£1.51 (-2.46%)Earnings
- Half Year 2023 Syncona Ltd Earnings Call TranscriptNov 17, 2022£1.78 (+3.01%)Earnings
- Syncona Ltd to Acquire Applied Genetic Technologies Corp Call TranscriptOct 24, 2022
- Full Year 2022 Syncona Ltd Earnings Call TranscriptJun 16, 2022£1.91 (+0.32%)Earnings
- Half Year 2022 Syncona Ltd Earnings Call TranscriptNov 11, 2021£2.04 (-0.73%)Earnings
- Full Year 2021 Syncona Ltd Earnings Call TranscriptJun 17, 2021£2.15Earnings
- Half Year 2021 Syncona Ltd Earnings Call TranscriptNov 19, 2020£2.6 (-2.62%)Earnings
- Full Year 2020 Syncona Ltd Earnings Call TranscriptJun 11, 2020£2.22 (-0.67%)Earnings
- Full Year 2020 Syncona Ltd Earnings Call - Q&A Session TranscriptJun 11, 2020£2.22 (-0.67%)Earnings
- Syncona Ltd Corporate Analyst Meeting TranscriptFeb 04, 2020
- Half Year 2020 Syncona Ltd Earnings Call TranscriptNov 21, 2019£2.21 (-1.56%)Earnings
Full Year 2022 Syncona Ltd Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to Syncona's full year results for 2021-2022 financial year. (Operator Instructions) I'd like to advise all participants that this call is being recorded.
I will now hand over to the CEO of Syncona Limited, Martin Murphy, to open the presentation. Martin, please go ahead.
Good morning, and welcome to Syncona's annual results. Before we step into the specifics of last year, I'd like to just step back and look at what we've achieved over the last 10 years. Syncona was founded back in 2012. And at that time, we set out with a very ambitious plan to transform the way in which innovative life science technology in the U.K. was commercialized through company creation and to thereby deliver economic returns and innovative new treatments for patients.
Since 2012, we've built 18 companies. We've delivered over GBP 900 million with attractive returns. And from a patient perspective, we've taken 3 products into pivotal trials, which is the last trial prior to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)